Estradiol News and Research

RSS

Estradiol is a sex hormone. Mislabelled the "female" hormone, it is also present in males; it represents the major estrogen in humans. Estradiol has not only a critical impact on reproductive and sexual functioning, but also affects other organs including the bones.

Estradiol and its metabolites and their association with knee osteoarthritis

Osteoarthritis, which usually develops between the ages of 40 and 50, is more prevalent in women. It is thought that sex hormones may play a role in developing the disease, since they can be involved in inflammation of the tissues affected by it.

26 Jul 2006

Estrogen and testosterone combination to treat menopause may increase risk of breast cancer

Women who take a combination of estrogen and testosterone to treat the symptoms of menopause may have an increased risk of breast cancer, according to an article in the July 24 issue of Archives of Internal Medicine.

25 Jul 2006

Endogenous sex hormones, cognitive decline and future dementia in old men

A prospective population-based study has found that higher estrogen levels in older men are associated with an increased risk of dementia. By contrast, levels of testosterone were not associated with cognitive decline.

24 Jul 2006

Combination of anastrozole and a synthetic hormone called goserelin may slow male breast cancer growth

Medical oncologists across the nation want to know whether a certain drug combination can slow the progression of male breast cancer, a rare disease that often goes undiagnosed until it's in an advanced stage.

10 Jul 2006

Exposure to environmental estrogens during development of the prostate gland in the male fetus may lead to later prostate cancer risk

A study in the June 1 issue of Cancer Research presents the first evidence that exposure to low doses of environmental estrogens during development of the prostate gland in the male fetus may result in a predisposition to prostate cancer later in life.

1 Jun 2006

Study shows rapid return to menstrual flow once oral contraception stopped

A study by a Columbia University Medical Center researcher shows that 99 percent of participants experienced either a return to menstruation or became pregnant within 90 days after stopping an investigational, low-dose oral contraceptive taken every day without placebo.

8 May 2006

$Men with low estrogen levels have an increased risk for future hip fracture$

Men with low estrogen levels have an increased risk for future hip fracture

A new study has found that men with low estrogen levels have an increased risk for future hip fracture, and those with both low estrogen and low testosterone levels have the greatest risk.

3 May 2006

Nimesulide fights breast cancer by targeting key enzyme

A pain-killing medication appears to halt the production of an enzyme that is key to a common form of breast cancer, a new study using tissue cultures suggests.

16 Apr 2006

PR Pharmaceuticals issued U.S. patent covering 2-methoxyestradiol for the treatment of diabetes

The patent which is assigned to the University of Pittsburgh has been exclusively licensed to PRP. The drug, known as PulmoLAR, containing 2ME as active ingredient, is currently developed by PRP for the treatment of pulmonary arterial hypertension (PAH).

21 Mar 2006

Blood clot warning to go on Ortho Evra birth control patch

The U.S. Food and Drug Administration (FDA) says early results of a new study show that women who use the Ortho Evra contraceptive patch are twice as likely to develop blood clots than others who took a birth control pill.

19 Feb 2006

First solid data on health effects of a low-fat diet

Adopting a low-fat diet in later life and following such a regimen for nearly a decade does not appear to have a significant impact on reducing the overall risk of breast cancer, colorectal cancer or heart disease, according to a Women's Health Initiative study that involved nearly 50,000 postmenopausal women across the United States.

9 Feb 2006

Hormone discovered in bird brains also plays major role in mammalian reproductive system

University of California, Berkeley, researchers have discovered a new actor in the mammalian reproductive system, a hormone that fills a role long suspected, but until now undetected.

7 Feb 2006

Warning of risk of from vaginal oestrogen

Breast cancer specialists from one of the UK's leading cancer centres cautioned doctors of the risks in prescribing vaginal oestrogen to breast cancer patients being treated with the new aromatase inhibiting drugs, anastrozole, letrozole and exemestane.

26 Jan 2006

Research indicates birth control pill could cause long-term problems with testosterone

In the January issue of The Journal of Sexual Medicine, researchers have published a new investigation measuring sex hormone binding globulin (SHBG) before and after discontinuation of the oral contraceptive pill.

6 Jan 2006

New research indicates birth control pill could cause long-term problems with testosterone

4 Jan 2006

Aromatase inhibitors may slow growth of lung cancer

A few years ago researchers discovered that, much like breast tumors, some lung tumors also thrive on estrogen. Now a medical student conducting research on a Howard Hughes Medical Institute (HHMI) fellowship and colleagues have managed to stop the growth of human lung cancer cells in mice with a class of breast cancer drugs called aromatase inhibitors.

15 Dec 2005

Warnings about blood clots with contraceptive patch

According to U.S. regulators, Johnson & Johnson's Ortho Evra contraceptive patch contains higher levels of a hormone known to cause blood clots than average birth control pills.

13 Nov 2005

Recent evidence suggests caution in prescribing hormone therapy for breast cancer

One of the most effective new treatments for breast cancer is a hormone therapy. Aromatase inhibitors work by powerfully blocking the conversion of androgen precursors into estrogens, which lowers estradiol levels in the bloodstream and estrogen levels in peripheral tissues.

4 Sep 2005

Contraceptive pill controls severe premenstrual disorder

According to a new study, a low dose oral contraceptive works as a treatment for the most severe form of premenstrual syndrome, premenstrual dysphoric disorder (PMDD).

1 Sep 2005

Low dose oral contraceptive effective in controlling premenstrual disorder

A new study led by researchers at Yale School of Medicine shows for the first time that a low dose oral contraceptive with a unique progestin and dosing regimen is effective in treating symptoms of premenstrual dysphoric disorder (PMDD), the most severe form of premenstrual syndrome.

31 Aug 2005